Huda Salman clinical trial pipeline

2 trials changed in the last 30 days: 2 stopped, 0 with notable changes, 0 with minor changes only.

1. Stopped

   Chimeric Antigen Receptor T Cell Therapy Redirected to CD4…Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML

   Recruitment suspended

   Huda Salman·Phase 1· NCT06071624· Registry history of NCT06071624 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

2. Stopped

   Chimeric Antigen Receptor T Cell Redirected to Target CD4…Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

   Recruitment suspended

   Huda Salman·Phase 1· NCT06197672· Registry history of NCT06197672 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.